



## PRESS RELEASE

### Trillium adds late stage preclinical program

Toronto, Canada – April 10, 2006 - Trillium Therapeutics Inc. (TTI) announced today that it has acquired rights to a novel development program from two leading hospitals in the United States.

TTI-1612 is a recombinant version of a naturally occurring protein with powerful cytoprotective and anti-inflammatory effects. Strong efficacy results have been demonstrated in a variety of models of gastrointestinal inflammation and damage.

“This program was particularly attractive to TTI because of the compelling scientific data, its short timeline and clear path to the clinic, and last but not least, the support and enthusiasm we found for this therapeutic approach among front-line clinicians”, said Trillium CEO Dr. Niclas Stiernholm.

In order to rapidly secure clinical material and advance this protein into human trials, TTI has entered into a license agreement with Xoma to access its proprietary microbial expression system. The company has secured a GMP manufacturing source and is assembling an international clinical focus group to assist with strategy and execution of clinical trials.

“The profile of TTI-1612 allows us to bring this product through early clinical development ourselves, creating significant shareholder value”, commented Dr. Bob Uger, Vice President, Research & Development. “Having secured manufacturing access quickly, we plan to be in clinical development by late 2007.”

#### About Trillium:

Trillium Therapeutics Inc. is a private research and development company specializing in innovative therapies that restore balance to the immune system in conditions associated with aberrant and harmful immune responses. These include autoimmune and inflammatory disorders, graft rejection, cancer and chronic viral diseases. TTI currently has two major scientific platforms encompassing five proprietary product opportunities at various stages of preclinical development. The first platform involves the recently identified CD200 immunoregulatory protein and its receptor. These represent novel targets for the treatment of a variety of autoimmune diseases and cancer. The second platform is focused on the activating receptor, FcγRIIa, implicated in several autoimmune diseases, including rheumatoid arthritis and lupus. The company has a

broad network of external academic and industry relationships, including some with major US and European biotechnology and pharmaceutical companies.

- 30 -

For more information, please contact:

Niclas Stiernholm, Ph.D.  
Chief Executive Officer  
Trillium Therapeutics Inc.  
96 Skyway Avenue  
Toronto, Ontario, M9W 4Y9  
Canada

Tel: (416) 595-0627  
Fax: (416) 595-5835  
[niclas@trilliumtherapeutics.com](mailto:niclas@trilliumtherapeutics.com)  
[www.trilliumtherapeutics.com](http://www.trilliumtherapeutics.com)